Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Body Mass Index (BMI) at Baseline: Subgroup Analysis of the SENSCIS Trial | A37. ILD THERAPY I - Jouneau, S; Lescoat, A; Riemekasten, G
Am J Respir Crit Care Med 2020; 2020201A1526. Im Internet (Stand: 20.07.2020):